Secular Growth Stands Out as Earnings Climate Cools
Jennison Associates’ Mark Baribeau, CFA, shares why the changing growth landscape should benefit growth stocks and which secular trends are shaping the future.
Innovation Accelerates Across the Healthcare Sector
Feb 3, 2023
Rising tech-enablement, research breakthroughs, and focus on better patient outcomes are reshaping healthcare.
In This Article
Highlights
- Innovation is modernizing the healthcare sector, as technology adoption is improving the patient experience, influencing lower costs.
- Advancements in the ability to diagnose, monitor, and treat diseases with personalized therapeutics is creating a broad set of investment opportunities.
- Value-based care models are helping patients by shifting the liability to the provider of care, which is encouraging technology investments and driving better outcomes.
- We believe the current wave of innovation is presenting opportunities for select companies with access to data to demonstrate durable, outsized growth over the next decade, similar to what we observed in the information technology sector from 2010 to 2020.
Currently, there are a handful of large tech conglomerates with entrenched competitive advantages. We expect this dynamic to play out in healthcare. Companies that can continue to innovate should benefit. Data will play a crucial function in defining winners. Over time, we expect the healthcare companies that can effectively collect, process, and make sense of data to emerge as the industry’s large conglomerates with established competitive advantages. For example, managed care organizations with hundreds of millions of members are able to collect patient data across different demographics and identify the best treatments for individual patients.
There are also early signs that more effective obesity treatments are having a positive impact on cardiovascular disease, which is among the world’s deadliest and most costly conditions to treat. For investors, these advancements are creating new opportunities among select pharmaceutical companies that have the depth of resources—including large balance sheets and sizeable manpower—to capitalize on this enormous market for cardiovascular treatments and prevention.
Additionally, the increase in publicly traded biotech and biopharma companies during the past five years is just one of many ways to gain exposure to potential breakthrough discoveries.
The global experience of COVID-19 highlighted that there has not been nearly enough investment in basic research to develop new treatments. As a result, funding has poured into healthcare innovation since the start of the pandemic. This R&D spending extends to companies along the healthcare supply chain and is creating a much broader investment opportunity set. As one example, the process of analyzing a molecule in a biotech company’s research lab requires, among other things, specialized chemicals and research tools produced by different types of companies.
Opportunities Emerging From Value-based Care Models
Innovation in healthcare is designed to improve access to care, quality of diagnosis, and patient outcomes, which collectively reduce costs across the healthcare system. At its core, these are the goals and catalysts for innovation in the sector. A shift towards a value-based care model where costs are directly associated with the quality of the result is encouraging technology investments to increase efficiencies.
Healthcare service providers are guiding this evolution, with access to patient data and developing methods to monitor and optimize the delivery of care.
You May Also Like
Why Are Growth Stocks Poised To Rebound?
Mark Baribeau, Head of Global Equity at Jennison Associates, discusses why slowing broader market earnings growth creates optimism for growth stocks in 2023.
The Fintech Opportunity in Emerging Markets
The emerging markets fintech industry offers exposure to secular growth, but each country is regulated differently, requiring local insights to navigate risks.
The views expressed herein are those of Jennison Associates LLC (“Jennison”) investment professionals at the time the comments were made and may not be reflective of their current opinions and are subject to change without notice. This commentary is not intended as an offer or solicitation with respect to the purchase or sale of any security or other financial instrument or any investment management services. This commentary does not constitute investment advice and should not be used as the basis for any investment decision. This commentary does not purport to provide any legal, tax, or accounting advice.
Certain information in this commentary has been obtained from sources believed to be reliable as of the date presented; however, we cannot guarantee the accuracy of such information, assure its completeness, or warrant such information will not be changed. The information contained herein is current as of the date of issuance (or such earlier date as referenced herein) and is subject to change without notice. The manager has no obligation to update any or all such information, nor do we make any express or implied warranties or representations as to the completeness or accuracy. Any projections or forecasts presented herein are subject to change without notice. Actual data will vary and may not be reflected here. Projections and forecasts are subject to high levels of uncertainty. Accordingly, any projections or forecasts should be viewed as merely representative of a broad range of possible outcomes. Projections or forecasts are estimated, based on assumptions, subject to significant revision, and may change materially as economic and market conditions change.
Prudential Investment Management Services LLC is a Prudential Financial company and FINRA member firm. Jennison Associates and PGIM, Inc. (PGIM) are registered investment advisors and Prudential Financial companies. PGIM Quantitative Solutions is the primary business name of PGIM Quantitative Solutions LLC, a wholly owned subsidiary of PGIM. PGIM Fixed Income and PGIM Real Estate are units of PGIM. © 2023 Prudential Financial, Inc. and its related entities. Jennison Associates, Jennison, PGIM Real Estate, PGIM, and the PGIM logo are service marks of Prudential Financial, Inc. and its related entities, registered in many jurisdictions worldwide
For compliance use only 1065609-00001-00